Oral Rigosertib for Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

April 30, 2016

Conditions
Head and Neck Squamous Cell CarcinomaAnal Squamous Cell CarcinomaLung Squamous Cell CarcinomaCervical Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaSkin Squamous Cell CarcinomaPenile Squamous Cell Carcinoma
Interventions
DRUG

rigosertib

Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).

Trial Locations (13)

10029

Mount Sinai Medical Center, New York

10467

Montefiore Medical Center, The Bronx

19104

University of Pennslvania Abramson Cancer Center, Philadelphia

22031

Virginia Cancer Specialists, PC, Fairfax

24153

Blue Ridge Cancer Care, Salem

43210

Ohio State University, James Cancer Hospital, Columbus

48109

University of Michigan Health System, Ann Arbor

75201

Mary Crowley Cancer Research Center, Dallas

80045

University of Colorado School of Medicine, Aurora

80220

Denver VA Medical Center-ECHCS, Denver

94305

Stanford Cancer Institute, Stanford

95817

University of California Davis Comprehensive Cancer Center, Sacramento

07018

Veterans Administration New Jersey Health Care System, East Orange

All Listed Sponsors
lead

Traws Pharma, Inc.

INDUSTRY

NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter